Akebia Therapeutics (AKBA) Cost of Revenue (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Cost of Revenue data on file, last reported at $12.3 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 61.18% year-over-year to $12.3 million in Q1 2026; TTM through Mar 2026 was $44.1 million, a 7.16% increase from a year earlier, with the FY2025 full-year figure at $39.5 million, up 45.43% from the prior year.
• Cost of Revenue for Q1 2026 stood at $12.3 million, down from $12.5 million in the prior quarter.
• Over the last five years, Cost of Revenue for AKBA reached as high as $38.3 million in Q3 2022 and fell as low as $5.1 million in Q3 2024.
• Historically, Cost of Revenue has averaged $15.1 million across 5 years, with a median of $12.3 million in 2026.
• Across the five-year window, Cost of Revenue jumped 452.16% in 2022 and tumbled 71.4% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $23.6 million in 2022, then plunged by 59.09% to $9.7 million in 2023, then climbed by 17.61% to $11.4 million in 2024, then advanced by 10.39% to $12.5 million in 2025, then dropped by 1.95% to $12.3 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $12.3 million in Q1 2026, $12.5 million in Q4 2025, and $9.4 million in Q3 2025.